The importance of preventing hepatitis C virus infection among injection drug users in the United States

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 18, Issue SUPPL., 1998, Pages

  Alter, Miriam J ^a,b   Moyer, Linda A ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Hepatitis C virus; Injection drug use; Prevention

Indexed keywords

ILLICIT DRUG;

ARTICLE; CHRONIC LIVER DISEASE; HEALTH EDUCATION; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION PREVENTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PRIORITY JOURNAL; RISK MANAGEMENT; UNITED STATES; VIRUS TRANSMISSION;

HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0032125134     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199802001-00003     Document Type: Article

References (31)

1. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995;15:41-63.
2. Farci P, Alter HJ, Govindarajan S, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992;258: 135-40.
3. Farci P, Alter HJ, Wong DC, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA 1994;91:7792-6.
4. Shimizu YK, Hijikata M, Iwamoto A, et al. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol 1994;68:1494-500.
5. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994;23:437-55.
6. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992;327:1899-905.
7. Shakil AO, Conry-Cantilena C, Alter HJ, et al. and the Hepatitis C Study Group. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. Ann Intern Med 1995;123:330-7.
8. Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995;15:5-14.
9. Alter MJ, Hadler SC, Judson FN, et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 1990;264:2231-5.
10. McQuillan GM, Alter MJ, Moyer LA, Lambert SB, Margolis HS. A population based serologic study of hepatitis C virus infection in the United States. In Rizzetto M, Purcell RH, Gerin JL, Verme G (eds). Viral hepatitis and liver disease. Turin: Edizioni Minerva Medica, 1997:267-70.
11. Alter MJ, Gerety RJ, Smallwood L, et al. Sporadic non-A. non-B hepatitis: frequency and epidemiology in an urban United States population. J Infect Dis 1982;145:886-93.
12. Alter MJ, Coleman PJ, Alexander WJ, et al. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. JAMA 1989;262:1201-5.
13. Thomas DL, Zenilman JM, Alter HJ, et al. Sexual transmission of hepatitis C virus among patients attending Baltimore sexually transmitted diseases clinics - an analysis of 309 sexual partnerships. J Infect Dis 1995;171:768-75.
14. Mast EE, Alter MJ. Hepatitis C. Semin Pediatr Infect Dis 1997;8: 17-22.
15. Donahue JG, Nelson KE, Munoz A, et al. Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland. Am J Epidemiol 1991; 134:1206-11.
16. Zeldis JB, Jain S, Kuramoto IK, et al. Seroepidemiology of viral infections among intravenous drug users in northern California. West J Med 1992;156:30-5.
17. Van den Hoek JAR, Van Haastrecht HJA, Goudsmit J, et al. Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam. J Infect Dis 1990;160:823-6.
18. Garfein RS, Vlahov D, Galai N, et al. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996;86:655-61.
19. Koester SK, Hoffer L. "Indirect sharing": additional HIV risks associated with drug injection. AIDS Public Policy J 1994;9:100-5.
20. Heimer R, Khoshnood K, Jariwalafreeman B, et al. Hepatitis in used syringes - the limits of sensitivity of techniques to detect hepatitis B virus (HBV) DNA, hepatitis C virus (HCV) RNA, and antibodies to HBV core and HCV antigens. J Infect Dis 1996;173: 997-1000.
21. Conry-Cantilena C, Vanraden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996;334:1691-6.
22. Hagan H, Des Jarlais DC, Friedman SR, et al. Reduced risk of hepatitis B and hepatitis C among injecting drug users participating in the Tacoma syringe exchange program. Am J Public Health 1995;85:1531-7.
23. Centers for Disease Control and Prevention. Hepatitis surveillance report no. 56. Atlanta: U.S. Department of Health and Human Services, Public Health Service, 1995:36.
24. Krawczynski K, Alter MJ, Tankersley DL, et al. Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis 1996;173:822-8.
25. Centers for Disease Control. Recommendations for follow-up of health-care workers after occupational exposure to hepatitis C virus. MMWR Morb Mortal Wkly Rep 1997;46:603-6.
26. U.S. Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Baltimore: Williams & Wilkins, 1996.
27. Valleroy LA, Weinstein B, Jones TS, et al. Impact of increased legal access to needles and syringes on community pharmacies' needle and syringe sales - Connecticut, 1992-1993. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:73-81.
28. Groseclose SL, Weinstein B, Jones TS, et al. Impact of increased legal access to needles and syringes on practices of injecting-drug users and police officers - Connecticut, 1992-1993. J AIDS 1995; 10:82-9.
29. Gostin LO, Lazzarini Z, Jones TS, Flaherty K. Prevention of HIV/AIDS and other blood-borne diseases among injection drug users: a national survey on the regulation of syringes and needles. JAMA 1997;277:53-62.
30. U.S. Public Health Service. HIV prevention bulletin: medical advice for persons who inject illicit drugs. Atlanta: Centers for Disease Control and Prevention, May 9, 1997.
31. Lundberg GD. New winds blowing for American drug policies [editorial]. JAMA 1997;278:946-7.